Investigational Drug Details
| Drug ID: | D050 |
| Drug Name: | Troglitazone |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00197 |
| DrugBank Description: | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. |
| PubChem ID: | 5591 |
| CasNo: | 97322-87-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O |
| Structure: |
|
| InChiKey: | GXPHKUHSUJUWKP-UHFFFAOYSA-N |
| Molecular Weight: | 441.54 |
| DrugBank Targets: | Peroxisome proliferator-activated receptor gamma; Estrogen-related receptor gamma; Steroid hormone receptor ERR1; Peroxisome proliferator-activated receptor delta; Peroxisome proliferator-activated receptor alpha; Glutathione S-transferase P; Long-chain-fatty-acid--CoA ligase 4; Plasminogen activator inhibitor 1; Equilibrative nucleoside transporter 1 |
| DrugBank MoA: | Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Troglitazone is a ligand to both PPARα and PPARγ, with a highter affinity for PPARγ. The drug also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity. Troglitazone has been shown to reduce inflammation, and is associated with a decrase in nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). Unlike sulfonylureas, troglitazone is not an insulin secretagogue. |
| DrugBank Pharmacology: | Troglitazone is an oral antihyperglycemic agent which acts primarily by decreasing insulin resistance. Troglitazone is used in the management of type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes). It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Troglitazone is not chemically or functionally related to either the sulfonylureas, the biguanides, or the g-glucosidase inhibitors. Troglitazone may be used concomitantly with a sulfonylurea or insulin to improve glycemic control. |
| DrugBank Indication: | For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00025 | 11443197 | J Clin Endocrinol Metab | Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? | Details |
| A00193 | 36646975 | Pediatr Nephrol | Dual diagnosis of autosomal dominant polycystic kidney disease and sickle cell disease in a teenage male. | Details |
| A00198 | 39746795 | Ren Fail | Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production. | Details |
| A00200 | 39804512 | Langenbecks Arch Surg | A hypocaloric protein-rich diet before metabolic surgery improves liver function in patients with obesity and diabetes : A secondary analysis of a randomized clinical trial. | Details |
| A00204 | 39873191 | Gut Microbes | Gut microbiota modulation via fecal microbiota transplantation mitigates hyperoxaluria and calcium oxalate crystal depositions induced by high oxalate diet. | Details |